摘要:
A hybrid rectifier that works as either a hybrid full bridge or a voltage doubler. Under 220 V AC input condition, the hybrid rectifier operates in full bridge mode, while at 110 V AC input, it operates as voltage doubler rectifier. The hybrid rectifier may be used with a DC-DC converter, such as an LLC resonant converter, in a power supply. With this mode switching, the LLC converter resonant tank design only takes consideration of 220 V AC input case, such that the required operational input voltage range is reduced, and the efficiency of the LLC converter is optimized. Both the size and power loss are reduced by using a single stage structure instead of the conventional two-stage configuration.
摘要:
Disclosed are half bridge inverter unit and inverter thereof. The half bridge inverter unit includes an inverter controlling module and inductors. The inverter controlling module provides different connection modes based on different operation modes so that the inverter meets the requirement of wide input voltage range as it can work in either voltage step-up mode or voltage step-down mode. The mid-point voltage between the DC series capacitors connected in parallel with DC power supply can be balanced automatically by taking advantage of the grid voltage symmetry with regard to positive and negative half cycles. The inverter is of single stage structure. It has advantages of low power loss, low cost, high efficiency and reliability.
摘要:
Disclosed is as a substituted thiazolamine derivative represented by Formula I or a pharmaceutically acceptable salt thereof or a hydrate thereof (the definitions of each group in the formula are as presented in the description), and the application thereof in the prevention and/or treatment of viral diseases induced by picornavirus. Also disclosed is a pharmaceutical composition containing the compound.
摘要:
Disclosed are pyridazine derivatives represented by Formula I or pharmaceutically acceptable salts or hydrates thereof, pharmaceutical compositions comprising the compounds, methods of treating and/or preventing diseases or disorders associated with viral infections in patients using the compounds, and the use of the compounds in preparing the medicaments for treating and/or preventing diseases or disorders associated with viral infections. The compounds represented by Formula I have antiviral activity, especially anti-microRNA viral activity. Symbols in the compounds represented are described in the specification.